Frühe effekte nach systemischer und intravitrealer bevacizumab (Avastin®)-therapie bei neovaskulärer altersbedingter makuladegeneration

Translated title of the contribution: Early effects of systemic and intravitreal bevacizumab (Avastin®) therapy for neovascular age-related macular degeneration

W. Geitzenauer, Stephan Michels, F. Prager, G. Kornek, L. Vormittag, Philip J Rosenfeld, U. Schmidt-Erfurth

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Purpose: The purpose of this study was to evaluate the early treatment response following systemic and intravitreal bevacizumab therapy in patients with neovascular age-related macular degeneration (AMD). Patients and Methods: In a prospective cohort study 12 eyes with neovascular AMD were treated with 5 mg/kg systemic bevacizumab, and 13 eyes with 1 mg intravitreal bevacizumab. Systemic therapy was given three times at 2-week intervals, intravitreal therapy up to three times at 4-week intervals. Patients were evaluated according to best corrected visual acuity (VA) and optical coherence tomography (OCT) at baseline as well as at week 1, week 4 and week 12 after therapy. Fluorescein angiography (FA) was performed at baseline and week 12. Results: Systemic and intravitreal bevacizumab therapy showed a treatment response within one week. Visual acuity improved at week 1 by 4.9 letters from baseline in the systemic and by 6.9 letters in the intravitreal treatment group. Central retinal thickness (CRT), as measured by OCT decreased by 51.9 μm and 176.4 μm, respectively. At month 3 a persistent treatment effect was detectable. Mean gain in visual acuity was 11 letters in the systemic and 8.3 letters in the intravitreal group, CRT had decreased by 100 μm and 153.8 μm, respectively. Leakage as evaluated by FA was significantly reduced or absent in all patients. Conclusion: The early treatment responses following systemic and intravitreal bevacizumab appear to be similar. Both groups show improvement in VA and decrease in CRT within 1 week and up to 3 months. Long-term follow-up is required to evaluate the safety and treatment durability of both treatment modalities using bevacizumab.

Original languageGerman
Pages (from-to)822-827
Number of pages6
JournalKlinische Monatsblatter fur Augenheilkunde
Volume223
Issue number10
DOIs
StatePublished - Oct 1 2006

Fingerprint

Macular Degeneration
Visual Acuity
Therapeutics
Fluorescein Angiography
Optical Coherence Tomography
Bevacizumab
Cohort Studies
Prospective Studies
Safety

Keywords

  • Anti-angiogenesis
  • Bevacizumab
  • Neovascular age-related macular degeneration
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Frühe effekte nach systemischer und intravitrealer bevacizumab (Avastin®)-therapie bei neovaskulärer altersbedingter makuladegeneration. / Geitzenauer, W.; Michels, Stephan; Prager, F.; Kornek, G.; Vormittag, L.; Rosenfeld, Philip J; Schmidt-Erfurth, U.

In: Klinische Monatsblatter fur Augenheilkunde, Vol. 223, No. 10, 01.10.2006, p. 822-827.

Research output: Contribution to journalArticle

Geitzenauer, W. ; Michels, Stephan ; Prager, F. ; Kornek, G. ; Vormittag, L. ; Rosenfeld, Philip J ; Schmidt-Erfurth, U. / Frühe effekte nach systemischer und intravitrealer bevacizumab (Avastin®)-therapie bei neovaskulärer altersbedingter makuladegeneration. In: Klinische Monatsblatter fur Augenheilkunde. 2006 ; Vol. 223, No. 10. pp. 822-827.
@article{d258b5cbce85474193896b9f698ad8f4,
title = "Fr{\"u}he effekte nach systemischer und intravitrealer bevacizumab (Avastin{\circledR})-therapie bei neovaskul{\"a}rer altersbedingter makuladegeneration",
abstract = "Purpose: The purpose of this study was to evaluate the early treatment response following systemic and intravitreal bevacizumab therapy in patients with neovascular age-related macular degeneration (AMD). Patients and Methods: In a prospective cohort study 12 eyes with neovascular AMD were treated with 5 mg/kg systemic bevacizumab, and 13 eyes with 1 mg intravitreal bevacizumab. Systemic therapy was given three times at 2-week intervals, intravitreal therapy up to three times at 4-week intervals. Patients were evaluated according to best corrected visual acuity (VA) and optical coherence tomography (OCT) at baseline as well as at week 1, week 4 and week 12 after therapy. Fluorescein angiography (FA) was performed at baseline and week 12. Results: Systemic and intravitreal bevacizumab therapy showed a treatment response within one week. Visual acuity improved at week 1 by 4.9 letters from baseline in the systemic and by 6.9 letters in the intravitreal treatment group. Central retinal thickness (CRT), as measured by OCT decreased by 51.9 μm and 176.4 μm, respectively. At month 3 a persistent treatment effect was detectable. Mean gain in visual acuity was 11 letters in the systemic and 8.3 letters in the intravitreal group, CRT had decreased by 100 μm and 153.8 μm, respectively. Leakage as evaluated by FA was significantly reduced or absent in all patients. Conclusion: The early treatment responses following systemic and intravitreal bevacizumab appear to be similar. Both groups show improvement in VA and decrease in CRT within 1 week and up to 3 months. Long-term follow-up is required to evaluate the safety and treatment durability of both treatment modalities using bevacizumab.",
keywords = "Anti-angiogenesis, Bevacizumab, Neovascular age-related macular degeneration, Vascular endothelial growth factor",
author = "W. Geitzenauer and Stephan Michels and F. Prager and G. Kornek and L. Vormittag and Rosenfeld, {Philip J} and U. Schmidt-Erfurth",
year = "2006",
month = "10",
day = "1",
doi = "10.1055/s-2006-926875",
language = "German",
volume = "223",
pages = "822--827",
journal = "Klinische Monatsblatter fur Augenheilkunde",
issn = "0023-2165",
publisher = "Ferdinand Enke Verlag",
number = "10",

}

TY - JOUR

T1 - Frühe effekte nach systemischer und intravitrealer bevacizumab (Avastin®)-therapie bei neovaskulärer altersbedingter makuladegeneration

AU - Geitzenauer, W.

AU - Michels, Stephan

AU - Prager, F.

AU - Kornek, G.

AU - Vormittag, L.

AU - Rosenfeld, Philip J

AU - Schmidt-Erfurth, U.

PY - 2006/10/1

Y1 - 2006/10/1

N2 - Purpose: The purpose of this study was to evaluate the early treatment response following systemic and intravitreal bevacizumab therapy in patients with neovascular age-related macular degeneration (AMD). Patients and Methods: In a prospective cohort study 12 eyes with neovascular AMD were treated with 5 mg/kg systemic bevacizumab, and 13 eyes with 1 mg intravitreal bevacizumab. Systemic therapy was given three times at 2-week intervals, intravitreal therapy up to three times at 4-week intervals. Patients were evaluated according to best corrected visual acuity (VA) and optical coherence tomography (OCT) at baseline as well as at week 1, week 4 and week 12 after therapy. Fluorescein angiography (FA) was performed at baseline and week 12. Results: Systemic and intravitreal bevacizumab therapy showed a treatment response within one week. Visual acuity improved at week 1 by 4.9 letters from baseline in the systemic and by 6.9 letters in the intravitreal treatment group. Central retinal thickness (CRT), as measured by OCT decreased by 51.9 μm and 176.4 μm, respectively. At month 3 a persistent treatment effect was detectable. Mean gain in visual acuity was 11 letters in the systemic and 8.3 letters in the intravitreal group, CRT had decreased by 100 μm and 153.8 μm, respectively. Leakage as evaluated by FA was significantly reduced or absent in all patients. Conclusion: The early treatment responses following systemic and intravitreal bevacizumab appear to be similar. Both groups show improvement in VA and decrease in CRT within 1 week and up to 3 months. Long-term follow-up is required to evaluate the safety and treatment durability of both treatment modalities using bevacizumab.

AB - Purpose: The purpose of this study was to evaluate the early treatment response following systemic and intravitreal bevacizumab therapy in patients with neovascular age-related macular degeneration (AMD). Patients and Methods: In a prospective cohort study 12 eyes with neovascular AMD were treated with 5 mg/kg systemic bevacizumab, and 13 eyes with 1 mg intravitreal bevacizumab. Systemic therapy was given three times at 2-week intervals, intravitreal therapy up to three times at 4-week intervals. Patients were evaluated according to best corrected visual acuity (VA) and optical coherence tomography (OCT) at baseline as well as at week 1, week 4 and week 12 after therapy. Fluorescein angiography (FA) was performed at baseline and week 12. Results: Systemic and intravitreal bevacizumab therapy showed a treatment response within one week. Visual acuity improved at week 1 by 4.9 letters from baseline in the systemic and by 6.9 letters in the intravitreal treatment group. Central retinal thickness (CRT), as measured by OCT decreased by 51.9 μm and 176.4 μm, respectively. At month 3 a persistent treatment effect was detectable. Mean gain in visual acuity was 11 letters in the systemic and 8.3 letters in the intravitreal group, CRT had decreased by 100 μm and 153.8 μm, respectively. Leakage as evaluated by FA was significantly reduced or absent in all patients. Conclusion: The early treatment responses following systemic and intravitreal bevacizumab appear to be similar. Both groups show improvement in VA and decrease in CRT within 1 week and up to 3 months. Long-term follow-up is required to evaluate the safety and treatment durability of both treatment modalities using bevacizumab.

KW - Anti-angiogenesis

KW - Bevacizumab

KW - Neovascular age-related macular degeneration

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=33845268234&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845268234&partnerID=8YFLogxK

U2 - 10.1055/s-2006-926875

DO - 10.1055/s-2006-926875

M3 - Article

C2 - 17063425

AN - SCOPUS:33845268234

VL - 223

SP - 822

EP - 827

JO - Klinische Monatsblatter fur Augenheilkunde

JF - Klinische Monatsblatter fur Augenheilkunde

SN - 0023-2165

IS - 10

ER -